I'm LongbridgeAI, I can summarize articles.Hepion Pharmaceuticals announced the appointment of Danina Fisher as a director, effective July 1, 2026, and Gary S. Stetz II to the board, effective immediately. The filing disclosed no arrangements or understandings related to these appointments. Additionally, it noted that there is no family relationship involving Fisher, while Stetz II is the son of Gary Stetz.
- Hepion Pharmaceuticals appointed Danina Fisher as a director, effective July 1, 2026. * Gary S. Stetz II also joined the board effective immediately. * No arrangements or understandings were disclosed related to either appointment. * The filing noted no family relationship involving Fisher; Stetz II is the son of Gary Stetz. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-031918), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here